CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Miro Sciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Miro Sciences Ltd
Level 4, 216 St Georges Terrace
Phone: +61 862682641p:+61 862682641 PERTH, WAS  6000  Australia Ticker: MSXMSX
Business Summary
Miro Sciences Ltd, formerly NeuroScientific Biopharmaceuticals Limited, is an Australia-based biotechnology company. The Company is focused on developing novel technologies targeted at immune-mediated inflammatory diseases with stem cell science. It has been developing solutions to address complex medical needs where current treatment options are limited or ineffective. Its StemSmart platform is a patented mesenchymal stem cell technology targeting immune-mediated inflammatory disorders, including refractory Crohn's disease. It is designed to regulate immune responses and reduce inflammation in affected tissues. The Company also develops EmtinB, a peptide-based therapeutic candidate targeting optic nerve diseases, including glaucoma. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-II, which is produced as part of the human body's innate immune response to cell injury.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20266/30/2026Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Christopher L.Ntoumenopoulos 12/5/2023 11/17/2023
Chief Executive Officer NathanSmith 7/28/2025 7/28/2025
Chief Financial Officer ChrisKnee 10/26/2026 10/26/2026
6 additional Officers and Directors records available in full report.

Business Names
Business Name
MSX
NSB

General Information
Outstanding Shares: 389,718,547 (As of 6/30/2026)
Shareholders: 1,407
Stock Exchange: ASX
Fax Number: +61 863821801


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026